The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia

Neuropsychopharmacology

Volumn 22, Issue 2, 2000, Pages 125-132

  Bertolino, Alessandro ^a   Breier, Alan ^a   Callicott, Joseph H ^a   Adler, Caleb ^a   Mattay, Venkata S ^a   Shapiro, Maxim ^a   Frank, Joseph A ^b   Pickar, David ^a   Weinberger, Daniel R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Dopamine; Dorsolateral prefrontal cortex; Evoked release; N acetylaspartate; Schizophrenia; Striatum

Indexed keywords

AMPHETAMINE; N ACETYLASPARTIC ACID; RACLOPRIDE;

ADULT; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CLINICAL TRIAL; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA;

ADULT; AMPHETAMINE; ASPARTIC ACID; CARBON RADIOISOTOPES; CORPUS STRIATUM; DOPAMINE; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEURONS; PREFRONTAL CORTEX; RACLOPRIDE; REFERENCE VALUES; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034142382     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00096-2     Document Type: Article

References (51)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., Van Dyck C.H., Charney D.S., Innis R.B., Laruelle M. Increased striatal dopamine transmission in schizophrenia. Confirmation in a second cohort Am J Psychiatry. 155:1998;761-767.
2. Akbarian S., Sucher N.J., Bradley D., Taffazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney W.E., Jones E.G. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci. 16:1996;19-30.
3. Bates T.E., Stranward M., Keelan J., Davey G.P., Munro P.M.G., Clark J.B. Inhibition of N-acetylaspartate production. Implications for 1H MRS studies Neuroreport. 7:1996;1397-1400.
4. Bertolino A., Callicott J.H., Elman I., Mattay V.S., Tedeschi G., Frank J.A., Breier A., Weinberger D.R. Regionally specific neuronal pathology in untreated patients with schizophrenia. A proton magnetic resonance spectroscopic imaging study Biol Psychiatry. 43:1998;641-648. a.
5. Bertolino A., Callicott J.H., Nawroz S., Mattay V.S., Duyn J.H., Tedeschi G., Frank J.A., Weinberger D.R. Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia. Neuropsychopharmacology. 18:1998;1-9. b.
6. Bertolino A., Esposito G., Callicott J.H., Mattay V.S., vVan Horn J.D., Frank J.A., Berman K.F., Weinberger D.R. 1H-MRSI correlates with rCBF activation during working memory in patients with schizophrenia. Neuroimage. 5:1997;281.
7. Bertolino A., Knable M.B., Saunders R.C., Callicott J.H., Kolachana B.S., Mattay V.S., Bachevalier J., Egan M.F., Frank J.A., Weinberger D.R. The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. Biol Psychiatry. 45:1999;660-667.
8. Bertolino A., Nawroz S., Mattay V.S., Duyn J.H., Moonen C.T.W., Barnett A.S., Frank J.A., Tedeschi G., Weinberger D.R. A specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry. 153:1996;1554-1563.
9. Braun A.R., Jaskiw G.E., Vladar K., Sexton R.H., Kolachana B.S., Weinberger D.R. Effects of ibotenic acid lesion of the medial prefrontal cortex on dopamine agonist-related behaviors in the rat. Pharm Biochem Behav. 46:1993;51-60.
10. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., De Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations. Evidence from a novel positron emission tomography method Proc Natl Acad Sci USA. 94:1997;2569-2574.
11. Buckley P.F., Moore C., Long H., Larkin C., Thompson P., Mulvany F., Redmond O., Stack J.P., Ennis J.T., Waddington J.L. 1H Magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia. Clinical neurodevelopmental and cognitive correlates Biol Psychiatry. 36:1994;792-800.
12. Callicott J.H., Eegan M.F., Bertolino A., Mattay V.S., Langheim F.J.P., Frank J.A., Weinberger D.R. Hippocampal N-acetylaspartate in unaffected siblings of patients with schizophrenia. A possible intermediate phenotype Biol Psychiatry. 44:1998;941-950.
13. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
14. Cendes F., Andermann F., Dubeau F., Matthews P.M., Arnold D.L. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging. Neurology. 49:1997;1525-1533.
15. Clark J.B. N-acetyl aspartate. A marker for neuronal loss or mitochondrial dysfunction Dev Neurosci. 20:1998;271-276.
16. Davis KL, Kahn RS, Ko G, Davidson M (1991): Dopamine in schizophrenia: A review and reconceptualization Am J Psychiatry 148:1474-1486.
17. Deicken R.F., Zhou L., Schuff N., Fein G., Weiner M.W. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol Psychiatry. 43:1998;483-488.
18. Del Arco A., Martinez R., Mora F. Amphetamine increases extracellular concentrations of glutamate in the prefrontal cortex of the awake rat. A microdialysis study Neurochem Res. 23:1998;1153-1158.
19. De Stefano N., Matthews P., Antel J.P., Preul M., Francis G., Arnold D.L. Chemical pathology of acute demyelinating lesions and its correlations with disability. Ann Neurol. 38:1995;901-909.
20. Deutch A.Y. The regulation of subcortical dopamine systems by the prefrontal cortex. Interactions of central dopamine systems and the pathogenesis of schizophrenia J Neural Transm Suppl. 36:1992;61-89.
21. Divac I., Kosmal A., Bjorklund A., Lindvall O. Subcortical projections to the prefrontal cortex in the rat as revealed by the horseradish peroxidase technique. Neuroscience. 3:1978;785-796.
22. Duyn J.H., Gillen J., Sobering G., van Zijl P.C., Moonen C.T.W. Multisection proton MR spectroscopic imaging of the brain. Radiology. 188:1993;277-282.
23. Eastwood S.L., McDonald B., Burnet P.W., Beckwith J.P., Kerwin R.W., Harrison P.J. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol Brain Res. 29:1995;211-223.
24. Flores G., Wood G.K., Liang J.J., Quirion R., Srivastava L.K. Enhanced amphetamine sensitivity and increased expression of dopamine D2 receptors in postpubertal rats after neonatal excitotoxic lesions of the medial prefrontal cortex. J Neurosci. 16:1996;7366-7375.
25. Goldman-Rakic P.S. Handbook of Physiology. The Nervous System:1987;373-417 American Physiological Society, Bethesda, MD.
26. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity. A hypothesis for the etiology of schizophrenia Neuroscience. 41:1991;1-24.
27. Hietala J., Syvalahti E., Vuorio K. Striatal dopamine D2 receptor binding characteristics in neuroleptic naive schizophrenics studied with positron emission tomography. Arch Gen Psychiatry. 51:1994;116-123.
28. Jaskiw G.E., Karoum F.K., Weinberger D.R. Persistent elevations in dopamine and its metabolites in the nucleus accumbens after mild subchronic stress in rats with ibotenic acid lesions of the medial prefrontal cortex. Brain Res. 534:1990;321-323.
29. Knable M.B., Egan M.F., Heinz A., Gorey J., Lee K.S., Coppola R., Weinberger D.R. Evidence for a relationship between altered dopaminergic function and negative symptoms in drug-free schizophrenic patients. An I-123 IBZM-SPECT study Br J Psychiatry. 171:1997;574-577.
30. Kornhuber J., Riederer P., Reynolds G.P., Beckmann H., Jellinger K., Gabriel E. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients. Relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms J Neural Transm. 75:1989;1-10.
31. Laruelle M., Abi-Dargham A., van-Dyck C.H., Gil R., D'Souza C.D., Erdos J., McKCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single-photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci. 93:1996;9235-9240.
32. Lee T., Seeman P., Toutellotte W.W., Farley I.J., Hornykiewicz O. Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature. 274:1978;897-900.
33. Maier M., Ron M.A., Barker G.J., Tofts P.S. Proton magnetic resonance spectroscopy. An in vivo method of estimating hippocampal neuronal depletion in schizophrenia Psychol Med. 25:1995;1201-1209.
34. Moffett J.R., Namboodiri M.A. Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. J Neurocytol. 24:1995;409-433.
35. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 281:1998;1349-1352.
36. Murase S., Grenhoff J., Chouvet G., Gonon F.G., Svensson T.H. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci Lett. 157:1993;53-56.
37. Najim I.M., Wang Y., Shedid D., Luders H.O., Ng T.C., Comair Y.G. MRS metabolic markers of seizures and seizure-induced neuronal damage. Epilepsia. 39:1998;244-250.
38. Nasrallah H.A., Skinner T.E., Schmalbrock P., Robitaille P.M. Proton magnetic resonance spectroscopy of the hippocampal formation in schizophrenia. A pilot study Br J Psychiatry. 165:1994;481-485.
39. Pettigrew J.W., Keshavan M.S., Panchalingam K., Strychor S., Kapla D.B., Tretta M.G., Allen M. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry. 48(6):1991;563-568.
40. Renshaw P.F., Yurgelun-Todd D.A., Tohen M.S.G., Cohen B.M. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am J Psychiatry. 152:1995;444-446.
41. Roberts A.C., De Salvia M.A., Wilkinson L.S., Collins P., Muir J.L., Everitt B.J., Robbins T.W. 6-hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test. Possible interactions with subcortical dopamine J Neurosci. 14:1994;2531-2544.
42. Rubin Y., LaPlaca M.C., Smith D.H., Thibault L.E., Lenkinski R.E. The effect of N-acetyl-aspartate on the intracellular calcium concentration in NTera2-neurons. Neurosci Lett. 198:1995;209-212.
43. Saunders R.C., Kolachana B., Bachevalier J., Weinberger D.R. Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine. Nature. 393:1998;169-171.
44. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area. 9(and occipital area 17. Arch Gen Psychiatry 52):1995;805-818.
45. Shim S.S., Bunney B.S., Shi W.X. Effects of lesions in the medial prefrontal cortex on the activity of midbrain dopamine neurons. Neuropsychopharmacology. 15:1996;437-441.
46. Stanley J.A., Williamson P.C., Drost D.J., Rylett R.J., Carr T.J., Malla A., Thompson R.T. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull. 22:1996;597-609.
47. Svensson T.H., Tung C.S. Local cooling of prefrontal cortex induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta Physiol Scand. 136:1989;135-136.
48. Urenjak J., Williams S.R., Gadian D.G., Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci. 13:1993;981-989.
49. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 44:1987;660-669.
50. Weinberger D.R. Cell Biology of the Hippocampal Formation in Schizophrenia. Biol Psychiatry. 45:1999;395-402.
51. Weinberger D.R., Berman K.F., Zec R.F. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow (rCBF) evidence. Arch Gen Psychiatry. 43:1986;114-125.